Evidence map›Paper›PMID 37313579›Full record

ReviewESC heart failure2023

Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review.

Niuniu Li, Qiang Wu, Juan Meng, Cheng Feng, Siwei Jiang, Meixia Chen, Wenhui Xu, Fei Wang, Yifan Zhang, Juncai Liu and 3 more

Open access · goldAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Niuniu LiDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Qiang WuDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Juan MengDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Cheng FengDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Siwei JiangDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Meixia ChenDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Wenhui XuDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Fei WangDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Yifan ZhangDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Juncai LiuDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Cheng XuDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Gaolin LiuWashington University in St. Louis, St. Louis, USA.
Hong GaoDepartment of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
Shenzhen Third People’s Hospital · CNWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary arterial hypertension-targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48-year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest distress after exercise for 1 week. He was diagnosed with CLF, PoPH, and HPS. After 7 weeks of macitentan treatment, the patient's activity tolerance, pulmonary artery systolic pressure, arterial partial pressure of oxygen (PaO

Indexed as

Hepatopulmonary SyndromeHypertension, PortalHypertension, PulmonaryPulmonary Arterial HypertensionHumansMalePyrimidinesSulfonamidesmacitentanPyrimidinesSulfonamidesHepatopulmonary syndromeLiver failureMacitentanPortopulmonary hypertension

Identifiers

PMID37313579
PMCPMC10375108
OpenAlexW4380576352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.